PANKU-BREAST01
Start here
Baili-Ballentine's bispecific ADC izalontamab brengitecan showed a cORR of 40.5% and mPFS of 8.2 months in the phase 3 PANKU-Breast01 study in HR+/HER2- advanced breast cancer. The comparator cORR was 20.2%, mPFS was extended by 4.2 months, and the risk of progression or death was reduced by 59% (HR=0.41); ILD occurred in 1.1% of patients, all grade 1-2. The marketing application for this new indication has been accepted, and the results were published in The Lancet and presented at the ESMO congress.
Excerpted from mp.weixin.qq.com
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comPickBaili-Ballentine's Izalontamab Brengitecan Phase 3 PANKU-Breast01 Results Published in The Lancet, cORR 40.5%, mPFS 8.2 Months
Baili-Ballentine's bispecific ADC izalontamab brengitecan showed a cORR of 40.5% and mPFS of 8.2 months in the phase 3 PANKU-Breast01 study in HR+/HER2- advanced breast cancer. The comparator cORR was 20.2%, mPFS was extended by 4.2 months, and the risk of progression or death was reduced by 59% (HR=0.41); ILD occurred in 1.1% of patients, all grade 1-2. The marketing application for this new indication has been accepted, and the results were published in The Lancet and presented at the ESMO congress.
- x.com#ESMO2026
- x.comPANKU-Breast01
- x.comPANKU-Breast01
Heat trend for this story
Heat now 81·Peak in the comparable set 144 (Oct 24 06:00)·Change over 24h in the comparable set -34%·Participants now 22
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.